BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18701506)

  • 1. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.
    Case M; Matheson E; Minto L; Hassan R; Harrison CJ; Bown N; Bailey S; Vormoor J; Hall AG; Irving JA
    Cancer Res; 2008 Aug; 68(16):6803-9. PubMed ID: 18701506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
    Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
    Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
    Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
    Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
    Sommerer F; Vieth M; Markwarth A; Röhrich K; Vomschloss S; May A; Ell C; Stolte M; Hengge UR; Wittekind C; Tannapfel A
    Oncogene; 2004 Jan; 23(2):554-8. PubMed ID: 14724583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
    Yamamoto T; Isomura M; Xu Y; Liang J; Yagasaki H; Kamachi Y; Kudo K; Kiyoi H; Naoe T; Kojma S
    Leuk Res; 2006 Sep; 30(9):1085-9. PubMed ID: 16533526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.
    Malinowska-Ozdowy K; Frech C; Schönegger A; Eckert C; Cazzaniga G; Stanulla M; zur Stadt U; Mecklenbräuker A; Schuster M; Kneidinger D; von Stackelberg A; Locatelli F; Schrappe M; Horstmann MA; Attarbaschi A; Bock C; Mann G; Haas OA; Panzer-Grümayer R
    Leukemia; 2015 Aug; 29(8):1656-67. PubMed ID: 25917266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
    Veit C; Genze F; Menke A; Hoeffert S; Gress TM; Gierschik P; Giehl K
    Cancer Res; 2004 Aug; 64(15):5291-300. PubMed ID: 15289335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
    Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
    Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.
    Barbosa TC; Andrade FG; Lopes BA; de Andrade CF; Mansur MB; Emerenciano M; Pombo-de-Oliveira MS
    Leuk Lymphoma; 2014 Jul; 55(7):1501-9. PubMed ID: 24067137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations.
    Davidsson J; Paulsson K; Lindgren D; Lilljebjörn H; Chaplin T; Forestier E; Andersen MK; Nordgren A; Rosenquist R; Fioretos T; Young BD; Johansson B
    Leukemia; 2010 May; 24(5):924-31. PubMed ID: 20237506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK inhibition overcomes acquired resistance to MEK inhibitors.
    Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
    Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
    Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
    Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
    Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperactive Ras in developmental disorders and cancer.
    Schubbert S; Shannon K; Bollag G
    Nat Rev Cancer; 2007 Apr; 7(4):295-308. PubMed ID: 17384584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.
    Yip-Schneider MT; Lin A; Marshall MS
    Biochem Biophys Res Commun; 2001 Feb; 280(4):992-7. PubMed ID: 11162624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
    Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
    Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.